Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR

Pancreatology

Volumn 9, Issue 5, 2009, Pages 577-582

  Streit, Sylvia ^a   Michalski, Christoph W ^a   Erkan, Mert ^a   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene expression profiling; Microarray technology; Pancreatic cancer; RT PCR; TGF signaling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CELL ADHESION MOLECULE; COLLAGEN TYPE 1; FIBRONECTIN; FLUOROURACIL; GELATINASE B; GEMCITABINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; LIPOCORTIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN BNIP3; PROTEIN S 100; SCLEROPROTEIN; SMAD PROTEIN; SPHINGOLIPID ACTIVATOR PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN;

CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CARCINOGENESIS; DNA MICROARRAY; FIBROGENESIS; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; STELLATE CELL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 68049108169     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000212084     Document Type: Article

References (55)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
2. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
3. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543.
4. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2006.
5. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor-α. J Clin Invest 1992; 90: 1352-1360.
6. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Beger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569.
7. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Büchler MW: Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996; 74: 35-42.
8. Friess H, Yamanaka Y, Kobrin MS, Do DA, Büchler MW, Korc M: Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1: 1413-1420.
9. Ito Y, Higashiyama S, Takeda T, Yamamoto Y, Wakasa KI, Matsuura N: Expression of heparin-binding epidermal growth factorlike growth factor in pancreatic adenocarcinoma. Int J Pancreatol 2001; 29: 47-52.
10. Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y, Büchler MW, Korc M: Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000; 273: 1019-1024.
11. Miyagawa J, Hanafusa O, Sasada R, Yamamoto K, Igarashi K, Yamamori K, Seno M, Tada H, Nammo T, Li M, Yamagata K, Nakajima H, Namba M, Kuwajima M, Matsuzawa Y: Immunohistochemical localization of betacellulin, a new member of the EGF family, in normal human pancreas and islet tumor cells. Endocr J 1999; 46: 755-764.
12. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Büchler MW, Johnson GR, Korc M: Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994; 54: 3959-3962.
13. Kolb A, Kleeff J, Arnold N, Giese NA, Giese T, Korc M, Friess H: Expression and differential signaling of heregulins in pancreatic cancer cells. Int J Cancer 2007; 120: 514-523.
14. MAQC Consortium: The MicroArray Quality Control (MAQC) project shows interand intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006; 24: 1151-1161.
15. Friess H, Ding J, Kleeff J, Liao Q, Berberat PO, Hammer J, Büchler MW: Identification of disease-specific genes in chronic pancreatitis using DNA array technology. Ann Surg 2001; 234: 769-779.
16. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, Büchler MW: Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60: 1180-1199.
17. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W, Hahn SA, Luttges J, Gress TM: Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005; 24: 6626-6636.
18. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-2896.
19. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH: Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-8622.
20. Iacobuzio-Donahue CA, Maitra A, Shen- Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH: Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160: 1239-1249.
21. Tan ZJ, Hu XG, Cao GS, Tang Y: Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray. World J Gastroenterol 2003; 9: 818-823. (Pubitemid 36531568)
22. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-2657.
23. Grutzmann R, Foerder M, Alldinger I, Staub E, Brummendorf T, Ropcke S, Li X, Kristiansen G, Jesnowski R, Sipos B, Lohr M, Luttges J, Ockert D, Kloppel G, Saeger HD, Pilarsky C: Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 2003; 443: 508-517.
24. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP, Lemoine NR: Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003; 201: 63-74.
25. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR: Characterization of gene expression profiles in intraductal papillary- mucinous tumors of the pancreas. Am J Pathol 2002; 160: 1745-1754. (Pubitemid 34525654)
26. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162: 1151-1162.
27. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, Schackert HK, Kloppel G, Saeger HD, Pilarsky C: Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 2005; 24: 5079-5088.
28. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS: Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002; 18: 405-412.
29. Brandt R, Grutzmann R, Bauer A, Jesnowski R, Ringel J, Lohr M, Pilarsky C, Hoheisel JD: DNA microarray analysis of pancreatic malignancies. Pancreatology 2004; 4: 587-597.
30. Massague J, Blain SW, Lo RS: TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
31. Truty MJ, Urrutia R: Basics of TGF-β and pancreatic cancer. Pancreatology 2007; 7: 423-435.
32. Friess H, Yamanaka Y, Büchler MW, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846-1856.
33. 1 in human pancreatic cancer. Dig Dis Sci 1999; 44: 1793-1802.
34. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Büchler MW, Falb D, Korc M: The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-5372.
35. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K: Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995; 270: 2008-2011.
36. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T, Saiki I: Tumor necrosis factor-α -induced IKK phosphorylation of NF-κ B p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003; 278: 36916-36923.
37. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H: Critical roles of threonine- 187 phosphorylation in cellular stressinduced rapid and transient activation of transforming growth factor-β -activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 2005; 280: 7359-7368.
38. Karin M, Greten FR: NF-κ B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
39. 1 -mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2008; 27: 1198-1207.
40. Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, Peters JM, Friess H, Folkman J, Huber PE: Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 2007; 104: 12890-12895.
41. Choo MK, Sakurai H, Koizumi K, Saiki I: TAK1-mediated stress signaling pathways are essential for TNF-α -promoted pulmonary metastasis of murine colon cancer cells. Int J Cancer 2006; 118: 2758-2764.
42. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A, Adler G: Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998; 115: 421-432.
43. Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC, Wilson JS: Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 1999; 44: 534-541.
44. Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maillet B, Kloppel G: Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer 1994; 69: 144-151.
45. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54.
46. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5: 329-339.
47. 5 integrins and promotes cell motility. Cancer Res 2002; 62: 5358-5364.
48. Tai IT, Dai M, Chen LB: Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 2005; 26: 908-915.
49. Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H: Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer 2005; 117: 51-58.
50. Yoshioka N, Fuji S, Shimakage M, Kodama K, Hakura A, Yutsudo M, Inoue H, Nojima H: Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene. Exp Cell Res 2002; 279: 91-99.
51. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W: Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004; 64: 844-856.
52. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA, Friess H: Periostin creates a tumor- supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007; 132: 1447-1464.
53. Okami J, Simeone DM, Logsdon CD: Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004; 64: 5338-5346.
54. Abe T, Toyota M, Suzuki H, Murai M, Akino K, Ueno M, Nojima M, Yawata A, Miyakawa H, Suga T, Ito H, Endo T, Tokino T, Hinoda Y, Imai K: Upregulation of BNIP3 by 5-aza- 2′ -deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 2005; 40: 504-510.
55. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24: 4421-4432.